Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October 2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Atacand
Agreement with Cheplapharm Completed
1 October 2018 07:00 BST
Agreement with Cheplapharm for rights to
Atacand in 28 European countries
completed
AstraZeneca has completed an agreement with
Cheplapharm Arzneimittel GmbH (Cheplapharm) for the
commercial rights to Atacand (candesartan
cilexetil) and Atacand Plus (fixed-dose
combination of candesartan cilexetil and
hydrochlorothiazide) in
Europe.
Under the terms of the agreement, AstraZeneca has received a
payment of $200 million
from Cheplapharm. A time-bound payment of $10 million as well as
sales-contingent milestones will also be payable. The present
value of the upfront and time-bound payments will be reported as
Other Operating Income in the company's financial statements in the
third quarter of 2018.
AstraZeneca will continue to manufacture and
supply Atacand and Atacand Plus under a supply agreement and will continue
to commercialise the medicines in all markets where it still holds
the rights.
About Atacand
Atacand (candesartan
cilexetil) is a selective, AT1 subtype angiotensin II receptor
antagonist blocker (ARB) that is indicated for the treatment of
hypertension and heart failure. Atacand is also
available in Europe as a
fixed-dose combination of candesartan cilexetil and
hydrochlorothiazide (Atacand Plus). Atacand is indicated for the management of
hypertension in adults and children/adolescents, as well as heart
failure in adults. Atacand
Plus is indicated for the
management of hypertension when monotherapy is not sufficiently
effective. Atacand was developed in collaboration with Takeda.
Each company holds the exclusive rights to the product in certain
markets. In other markets, Atacand is co-marketed by both
parties.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203 749 5916
|
|
Jacob
Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
Cardiovascular; Metabolism
|
+44 203 749 5711
|
|
Nick
Stone
|
Respiratory; Renal
|
+44 203 749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203 749 5631
|
|
Craig
Marks
|
Finance; Fixed Income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Retail Investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 7277
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
01 October
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|